<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792934</url>
  </required_header>
  <id_info>
    <org_study_id>2012-073</org_study_id>
    <nct_id>NCT01792934</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases</brief_title>
  <acronym>ORCHESTRA</acronym>
  <official_title>A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare overall survival rates of colorectal cancer patients
      with multi-organ metastases with an indication for first line systemic treatment randomized
      for treatment with combination chemotherapy or treatment with combination chemotherapy and
      additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE and
      SBRT, depending on best clinical judgement according to a standardized treatment algorithm.
      Our hypothesis is that maximal tumor debulking in addition to systemic treatment with
      chemotherapy and biologicals will provide an improvement in progression free and overall
      survival in this patient group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from date of study inclusion until the date of death or until the end of follow up, assessed up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rates</measure>
    <time_frame>date of study inclusion to the first event defined as local recurrence or progression, distant recurrence or death from any cause assessed up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>assessed every 3 months, after a follow up of 3 years assessed every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy of the additional local treatment measured by number of serious adverse events.</measure>
    <time_frame>assessed after inclusion of 25, 50 and 100 patients, after 30% of the patients are included in the study for 12 months and after the end of follow up, assessed up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">478</enrollment>
  <condition>Multi-organ Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX or FOLFOX regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX regimen according to standard procedures</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen according to standard procedures</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radiofrequency ablation (RFA)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy (SBRT)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>may be added to both regimens according to standard procedures</description>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor biopsy</intervention_name>
    <description>at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy</description>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological documentation of cancer is required.

          -  Indication for first line palliative systemic treatment for metastatic colorectal
             cancer (mCRC).

          -  Patients with CRC metastases in (the primary tumor is excluded as metastatic site)

               -  ≥ 2 different organs if at least &gt;1 extra-hepatic metastases or

               -  ≥ 2 different organs including &gt;5 hepatic metastases not located to one lobe or

               -  ≥ 2 different organs including either a positive para-aortal lymph nodes or
                  celiac lymph nodes or adrenal metastases or pleural carcinomatosis or peritoneal
                  carcinomatosis

          -  Feasible radical tumor debulking. Incomplete tumor debulking is allowed only if at
             least 80% of metastases can be treated.

          -  To meet the inclusion criteria a cytological analysis should be performed in case of
             any uncertainty about the presence of a lesion e.g. a false positive or false negative
             result on imaging.

          -  Age ≥ 18 years.

          -  WHO performance status 0 - 1.

          -  Life expectancy of at least 12 weeks.

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  Hemoglobin ≥ 5.6 mmol/L;

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3;

               -  Platelet count ≥ 100*109/l;

               -  Total bilirubin ≤ 1.5 times the upper limit of normal;

               -  ALT and AST ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for
                  subjects with liver involvement of their cancer);

               -  Albumin &gt; 30 g/l;

               -  Serum creatinine ≤ 1.5 x upper limit of normal or a MDRD ≥ 50 ml/min;

               -  Prothrombin time or INR &lt; 1.5 x ULN, unless coumarin derivates are used. Due to
                  interactions with capecitabine, all patients using coumarin derivates will be
                  treated with LMWH instead.

               -  Activated partial thromboplastin time &lt; 1.25 x ULN (therapeutic anticoagulation
                  therapy is allowed if this treatment can be interrupted as judged by the treating
                  physician).

          -  Written informed consent.

        Exclusion Criteria:

          -  Prior (neo-)adjuvant chemotherapy for &lt; 6 months after last treatment and first
             detection of extra-hepatic metastases, except for neoadjuvant capecitabine in the
             context of chemoradiation for rectal carcinoma.

          -  Candidates for HIPEC.

          -  Patients with liver metastases only

          -  Evidence of brain metastases.

          -  History of other prior malignancy except for adequately treated basal cell or squamous
             cell skin cancer or in situ cervical cancer. Patients with other malignancies are
             eligible if they have remained disease free for at least 5 years.- History of cardiac
             disease:

               -  Congestive heart failure &gt;NYHA class 2;

               -  Active Coronary Artery Disease (defined as myocardial infarction within 6 months
                  prior to screening);

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin
                  are permitted).

          -  Uncontrolled hypertension. Blood pressure must be ≤160/95 mm Hg at the time of
             screening on a stable antihypertensive regimen. Blood pressure must be stable on at
             least 3 separate measurements on at least 2 separate days.

          -  Uncontrolled infections (&gt; grade 2 NCI-CTC version 4.0).

          -  Pregnant or breast-feeding women. Women of childbearing potential must have a negative
             pregnancy test performed within 7 days of the start of treatment. Both men and women
             enrolled in this trial must agree to use adequate barrier birth control measures
             (e.g., cervical cap, condom, and diaphragm) or intrauterine device during the course
             of the trial. Oral birth control methods alone will not be considered adequate on this
             study, because of the potential pharmacokinetic interaction between study drug and
             oral contraceptives. Concomitant use of oral and barrier contraceptives is advised.

          -  Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy
             during the study or within 4 weeks of the start of study drug.

          -  Concomitant use of dexamethasone, anticonvulsants and anti-arrhythmic drugs other than
             digoxin or beta blockers.

          -  Severe allergy for contrast media not controlled with premedication.

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the subject's participation in the study or evaluation of the study results.

          -  Any condition that is unstable or could jeopardize the safety of the subject and their
             compliance in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.M.W. Verheul, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H.M.W. Verheul, MD PhD</last_name>
    <phone>0031 (0)20 4444321</phone>
    <email>h.verheul@vumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Noordwest Ziekenhuis Groep</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MP Hendriks, Dr</last_name>
    </contact>
    <investigator>
      <last_name>MP Hendriks, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Hoekstra, R</last_name>
    </contact>
    <investigator>
      <last_name>R Hoekstra, R</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HJ Bloemendal, HJ</last_name>
    </contact>
    <investigator>
      <last_name>HJ Bloemendal, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amstelveen Ziekenhuis</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AA van Zweeden, Drs</last_name>
    </contact>
    <investigator>
      <last_name>AA van Zweeden, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.M.W. Verheul, MD, PhD</last_name>
      <phone>0031-20-4444321</phone>
      <email>h.verheul@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>H.M.W. Verheul, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PJ Tanis, Dr</last_name>
    </contact>
    <investigator>
      <last_name>PJ Tanis, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JM Meerum Terwogt, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JM Meerum Terwogt, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Ten Tije, Dr</last_name>
    </contact>
    <investigator>
      <last_name>A Ten Tije, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HH Helgason, Dr</last_name>
    </contact>
    <investigator>
      <last_name>HH Helgason, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H Torrenga, Dr</last_name>
    </contact>
    <investigator>
      <last_name>H Torrenga, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweizer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Trajkovic, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Trajkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G Vreugdenhil, Dr</last_name>
    </contact>
    <investigator>
      <last_name>G Vreugdenhil, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAP Hospers, Prof Dr</last_name>
    </contact>
    <investigator>
      <last_name>GAP Hospers, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spaarne ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Beeker, Drs.</last_name>
    </contact>
    <investigator>
      <last_name>A Beeker, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Polee, Dr</last_name>
    </contact>
    <investigator>
      <last_name>M Polee, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RLH Jansen, Dr</last_name>
    </contact>
    <investigator>
      <last_name>RLH Jansen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Los, Dr</last_name>
    </contact>
    <investigator>
      <last_name>M Los, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Sint Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SA Radema, Dr</last_name>
    </contact>
    <investigator>
      <last_name>SA Radema, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troost</last_name>
    </contact>
    <investigator>
      <last_name>Troost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL-3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Verhoef, MD PhD</last_name>
      <phone>0031 (0)10 7040704</phone>
      <email>c.verhoef@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>C. Verhoef, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P Hamberg, Dr</last_name>
    </contact>
    <investigator>
      <last_name>P Hamberg, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IJsselland ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vermaas</last_name>
    </contact>
    <investigator>
      <last_name>Vermaas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TC Kok, Dr</last_name>
    </contact>
    <investigator>
      <last_name>TC Kok, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tweesteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Beerepoot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>L Beerepoot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Ten Bokkel Huinink, Dr</last_name>
    </contact>
    <investigator>
      <last_name>D Ten Bokkel Huinink, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitait Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>IHM Borel Rinkes, Prof Dr</last_name>
    </contact>
    <investigator>
      <last_name>IHM Rinkes, IHM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Hospital</name>
      <address>
        <city>Vlissingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Halteren</last_name>
    </contact>
    <investigator>
      <last_name>van Halteren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Zaltbommel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JFM Pruijt, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JFM Pruijt, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JWB de Groot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JWB de Groot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>H.M.W. Verheul</investigator_full_name>
    <investigator_title>Head Department Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Debulking, cytoreduction, RFA, SABR, palliative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

